Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02428400
Other study ID # TG1050.02
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date October 2015
Est. completion date November 2018

Study information

Verified date November 2018
Source Transgene
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Methodology:

This is a double-blind, randomized, placebo-controlled, multi-cohort Phase 1/1b study in patients that are currently being treated for chronic HBV infection. For all cohorts, patients must be receiving antiviral treatment with either tenofovir disoproxil fumarate (TDF) or entecavir (ENT) for at least two years, and have their HBV infection well-controlled


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date November 2018
Est. primary completion date November 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- 18 through 65 years of age, inclusive

- Patients must be undetectable for neutralizing antibodies to Adenovirus serotype 5 (Ad5) (PART A ONLY)

- Negative serum ß-HCG (for women of childbearing potential only; women of non-childbearing potential are defined as a woman who has been postmenopausal for = 2 years or who had had a hysterectomy, bilateral oophorectomy, or medically documented ovarian failure)

- Female patients of childbearing potential must be willing to use double effective methods of contraception (e.g. two of the following: hormonal contraception, condom or occlusive cap, intrauterine device (IUD) or intrauterine system (IUS), male sterilisation, or true abstinence) through 3 months after the last IMP administration; male patients must agree to use a double effective method of contraception (e.g. two of the following: hormonal contraception, condom or occlusive cap, IUD or IUS, male sterilisation, or true abstinence) during heterosexual intercourse with a partner capable of becoming pregnant throughout 3 months after the last IMP administration

- Currently on treatment for HBV monoinfection (any HBV genotypes) for at least 2 years with either the nucleos(t)ide analogue TDF or ENT

- A history of HBV DNA < 20 IU/mL for at least 6 months before entry and HBV DNA < 20 IU/mL at screening.

- HBsAg positive

- HBeAg positive or HBeAg negative patients with HBV infection

- Compensated liver disease; defined as direct or conjugated bilirubin = 1.2 × ULN, PT/INR = 1.2 × ULN, platelets = 150,000/mm3, serum albumin = 3.5 g/L, and no prior history of clinical hepatic decompensation (eg, ascites, jaundice, encephalopathy, variceal hemorrhage)

- ALT = 1.5 x ULN. Due to its biological variability, a re-test of the ALT parameter is allowed if the ALT value at screening does not exceed 10% of the 1.5 x ULN value and all other eligibility criteria are met. In this case, the ALT re-test can be performed no more than one month after the initial ALT screening assay and has to be confirmed within 2 weeks. Values of the two ALT assays re-tests have to be below 1.5 x ULN to include the patient. In case of re-test of the ALT parameter, all hematology and biochemistry parameters will be reassessed in parallel of the second ALT re-test to ensure that they are still matching TG1050.02 eligibility criteria.• Hemoglobin = 10 g/L

- Creatinine clearance > 50mL/min

- Neutrophils = 1,500/mm3

- Signed, written Independent Ethics Committee (IEC)-approved informed consent

Exclusion Criteria:

- Patients with any evidence of hepatocellular carcinoma or any other liver cancer

- Patients with a-fetoprotein > 50 ng/mL

- Patients co-infected with human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis Delta virus (HDV)

- Patients with either a) medical history or evidence of cirrhosis who had any biopsy showing cirrhosis or any approved non-invasive test indicative of cirrhosis as documented in the medical source documents; OR b) either of the following at screening: transient elastography score = 10.5 kPa OR a Fibrotest® Fibrosure® score of = 0.48 and an aspartate aminotransferase platelet ratio Index (APRI) of =1. Note: If a biopsy or non-invasive test has never been performed or if a biopsy or non-invasive test has been performed but showed no cirrhosis, then b) must be followed at screening

- Patients with a history of uncontrolled thyroid disease or abnormal thyroid stimulating hormone (TSH) levels at screening (defined as < 0.8 × lower limit of normal [LLN] or > 1.2 × ULN; patients are eligible with abnormal TSH levels if the free triiodothyronine (FT3) and free thyroxine (FT4) are within normal limits)

- Significant concomitant medical disorder including active systemic infection or proven or suspected immunosuppressive disorder

- History of immunodeficiency or autoimmune disease (including autoimmune hepatitis, or preexisting autoimmune or antibody-mediated disease)

- Current or history of clinically significant oncologic, pulmonary, hepatic, gastrointestinal, renal, cardiovascular, metabolic, endocrine, neurologic, hematologic illness, major organ transplantation, or any other major medical disorder that, in the judgment of the investigator, would interfere with patient treatment, or preclude patient participation in this study; should be discussed case by case with the Sponsor

- Pregnant or breast-feeding women

- Prior treatment with an experimental gene therapy product or a gene therapy product

- Prior participation in another research protocol involving an investigation medicinal product (IMP) within 4 months prior to TG1050/placebo injection

- History of substance abuse, including alcohol abuse that in the judgment of the investigator would deem the patient as not be suitable for participation in the study

- Patients unable or unwilling to comply with the protocol requirements

All key inclusion and exclusion criteria remain the same for patients in Part A, MD Cohort and in Part B of the study except for the following:

Patients with detectable or undetectable anti-Ad5 neutralizing antibodies are eligible (i.e. regardless of their pre-immunity to Ad5 nAb).

Study Design


Intervention

Biological:
TG1050
TG1050: adenovirus serotype 5 vector based immunotherapeutic product in adenovirus reference material (ARM) buffer
Placebo
Placebo: adenovirus reference material (ARM) buffer

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Transgene

Countries where clinical trial is conducted

Canada,  France,  Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and tolerability of TG1050 administered as single or multiple doses: Overall number of AEs, including SAEs, Grade 3 or 4 AEs, Grade 3 or 4 laboratory abnormalities, and any AE leading to a permanent discontinuation of IMP for any reason. Week 54
Primary Dosage of TG1050/placebo administration for investigation in Part B of the study will be determined. Week 54
See also
  Status Clinical Trial Phase
Recruiting NCT04496882 - Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue Phase 4
Completed NCT04083716 - A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults Phase 1
Not yet recruiting NCT03038802 - A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection Phase 1/Phase 2
Completed NCT05310487 - Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects Phase 1
Recruiting NCT06070051 - Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy Phase 1
Terminated NCT05001022 - A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects Phase 1
Recruiting NCT04139850 - The Establishment of Korean Hepatitis B Patients Cohort
Recruiting NCT05343481 - Efficacy of VTP-300 in Chronic Hepatitis B Infection Phase 2
Not yet recruiting NCT05490836 - Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients N/A
Recruiting NCT04543565 - Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study Phase 3
Active, not recruiting NCT02894918 - A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs Phase 4
Not yet recruiting NCT02793791 - Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients N/A
Recruiting NCT02287857 - Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B N/A
Recruiting NCT01965418 - A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Phase 4
Recruiting NCT01491295 - Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Phase 4
Terminated NCT01872988 - Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma Phase 3
Recruiting NCT01487876 - Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients Phase 2
Completed NCT01531166 - A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon N/A
Not yet recruiting NCT01436539 - Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Phase 4
Recruiting NCT01360879 - Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease N/A